Patten & Patten Inc. TN Lowers Stock Holdings in Edwards Lifesciences Corporation $EW

Patten & Patten Inc. TN decreased its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 9.9% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 133,993 shares of the medical research company’s stock after selling 14,768 shares during the period. Patten & Patten Inc. TN’s holdings in Edwards Lifesciences were worth $10,480,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Jennison Associates LLC raised its position in Edwards Lifesciences by 34.3% during the first quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock valued at $731,036,000 after purchasing an additional 2,576,383 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Edwards Lifesciences by 4.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,783,568 shares of the medical research company’s stock valued at $491,673,000 after purchasing an additional 264,311 shares in the last quarter. Nuveen LLC purchased a new position in shares of Edwards Lifesciences in the first quarter worth about $330,881,000. Invesco Ltd. increased its holdings in shares of Edwards Lifesciences by 2.6% in the first quarter. Invesco Ltd. now owns 4,287,712 shares of the medical research company’s stock worth $310,773,000 after buying an additional 107,241 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Edwards Lifesciences by 5.3% in the first quarter. Charles Schwab Investment Management Inc. now owns 3,961,643 shares of the medical research company’s stock worth $287,140,000 after buying an additional 198,882 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Down 0.6%

NYSE EW opened at $72.92 on Thursday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The stock has a market capitalization of $42.81 billion, a PE ratio of 10.49, a PEG ratio of 3.52 and a beta of 1.05. Edwards Lifesciences Corporation has a 1 year low of $64.89 and a 1 year high of $83.00. The business’s 50-day moving average is $77.72 and its 200 day moving average is $76.14.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.05. The company had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.Edwards Lifesciences’s quarterly revenue was up 11.9% on a year-over-year basis. During the same period last year, the firm earned $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Sell-side analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on EW. Mizuho lifted their price objective on Edwards Lifesciences from $87.00 to $95.00 and gave the stock an “outperform” rating in a report on Friday, July 25th. Robert W. Baird lifted their price objective on Edwards Lifesciences from $78.00 to $79.00 and gave the stock a “neutral” rating in a report on Friday, July 25th. Stifel Nicolaus set a $85.00 price objective on Edwards Lifesciences and gave the stock a “buy” rating in a report on Monday, September 22nd. Canaccord Genuity Group lifted their price objective on Edwards Lifesciences from $75.00 to $81.00 and gave the stock a “hold” rating in a report on Friday, July 25th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $87.06.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider directly owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. The trade was a 4.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the sale, the vice president directly owned 22,002 shares in the company, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.